Venture capital activity is surging with Andreessen Horowitz raising $15 billion to reach $90 billion in assets under management, while AI startups like Cyera achieve rapid valuation growth from $6B to $9B in six months. The funding environment reflects strong investor appetite for enterprise AI solutions and evolving biotech companies that can navigate regulatory pathways to commercial viability.
